Get the Stockscreener App
14.19
2.17%
-0.325
Overview
News
Price History
Option Chain
Financials
Why KVUE Down?
Discussions
Forecast
Dividend History
Kenvue Inc stock is traded at $14.19, with a volume of 50.01M.
It is down -2.17% in the last 24 hours and down -13.13% over the past month.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
See More
Previous Close:
$14.51
Open:
$14.34
24h Volume:
50.01M
Relative Volume:
1.71
Market Cap:
$27.22B
Revenue:
$15.14B
Net Income/Loss:
$1.42B
P/E Ratio:
19.27
EPS:
0.7361
Net Cash Flow:
$1.63B
1W Performance:
-6.55%
1M Performance:
-13.13%
6M Performance:
-39.29%
1Y Performance:
-37.69%
1-Day Range:
$14.09
$15.08
1-Week Range:
$14.09
$15.33
52-Week Range:
$14.05
$25.17
Kenvue Inc Stock (KVUE) Company Profile
Name
Kenvue Inc
Sector
Industry
Phone
908-874-1200
Address
1 KENVUE WAY, SUMMIT
Compare KVUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KVUE
Kenvue Inc
|
14.18 | 27.85B | 15.14B | 1.42B | 1.63B | 0.7361 |
|
PG
Procter Gamble Co
|
148.59 | 353.71B | 84.93B | 16.86B | 14.94B | 6.8506 |
|
UL
Unilever Plc Adr
|
60.85 | 151.82B | 64.99B | 6.71B | 6.53B | 2.4355 |
|
CL
Colgate Palmolive Co
|
75.66 | 62.35B | 20.00B | 3.05B | 3.37B | 3.5578 |
|
KMB
Kimberly Clark Corp
|
117.04 | 40.03B | 18.88B | 2.38B | 2.10B | 7.2549 |
Kenvue Inc Stock (KVUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-26-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Apr-10-25 | Initiated | Redburn Atlantic | Neutral |
| Mar-24-25 | Initiated | Evercore ISI | In-line |
| Jan-06-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-12-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-24-24 | Initiated | Jefferies | Buy |
| Sep-24-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-28-24 | Resumed | Citigroup | Neutral |
| Apr-11-24 | Initiated | Bernstein | Underperform |
| Apr-03-24 | Initiated | William Blair | Mkt Perform |
| Mar-01-24 | Resumed | Goldman | Neutral |
| Nov-17-23 | Initiated | Piper Sandler | Neutral |
| Sep-11-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-07-23 | Initiated | Canaccord Genuity | Buy |
| Sep-06-23 | Initiated | Argus | Hold |
| Aug-24-23 | Upgrade | Goldman | Neutral → Buy |
| Jul-25-23 | Initiated | Edward Jones | Buy |
| Jun-01-23 | Initiated | HSBC Securities | Hold |
| May-30-23 | Initiated | BofA Securities | Buy |
| May-30-23 | Initiated | Citigroup | Neutral |
| May-30-23 | Initiated | Deutsche Bank | Hold |
| May-30-23 | Initiated | Exane BNP Paribas | Neutral |
| May-30-23 | Initiated | Goldman | Neutral |
| May-30-23 | Initiated | JP Morgan | Overweight |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Initiated | UBS | Neutral |
View All
Kenvue Inc Stock (KVUE) Latest News
Deutsche Bank Lowers Kenvue (KVUE) PT to $18, Keeps a Hold Rating - Insider Monkey
Kenvue Hires P&G Exec to Aid Rebound From Tylenol Fallout - Bloomberg.com
The Scoop: Amazon’s layoff memo cuts through public speculation - PR Daily
Texas Sues Tylenol Over Alleged Autism Link - Northwest Signal
Kenvue Keeps Quarterly Dividend at $0.2075 a Share, Payable Nov. 26 to Holders of Record Nov. 12 - MarketScreener
Trump Trade: Texas sues Kenvue, J&J over Tylenol autism risk - TipRanks
Canaccord downgrades Tylenol maker Kenvue as legal risks cloud turnaround - Investing.com
Kenvue Inc. Declares Quarterly Cash Dividend, Payable on November 26, 2025 - MarketScreener
Leading vs lagging indicators on Kenvue Inc. performanceQuarterly Market Summary & Daily Stock Trend Watchlist - newser.com
Will Kenvue Inc. stock outperform tech sector in 2025Buy Signal & Breakout Confirmation Trade Signals - newser.com
Mizuho Markets Americas LLC Decreases Stock Holdings in Kenvue Inc. $KVUE - MarketBeat
Canaccord Genuity Downgrades Kenvue to Hold From Buy, Adjusts Price Target to $15 From $26 - MarketScreener
Kenvue downgraded to Hold at Canaccord amid negative headlines - TipRanks
Kenvue Declares Quarterly Cash Dividend - Bluefield Daily Telegraph
Kenvue (KVUE): Assessing Valuation as Legal Risks and Leadership Shifts Raise New Questions - Yahoo Finance
How Kenvue Inc. stock performs in weak economyGDP Growth & Step-by-Step Trade Execution Guides - newser.com
Texas Sues Kenvue, Alleging Deceptive Tylenol Marketing - The Business of Fashion
Teacher Retirement System of Texas Has $18.91 Million Stock Holdings in Kenvue Inc. $KVUE - MarketBeat
D.A. Davidson & CO. Sells 74,699 Shares of Kenvue Inc. $KVUE - MarketBeat
Texas sues Tylenol makers J&J and Kenvue, claiming they hid drug's autism risks | Health | swoknews.com - The Lawton Constitution
Paxton sues Tylenol company over autism claims - Marshall News Messenger
Texas sues Johnson & Johnson over Tylenol autism warningsCHOSUNBIZ - Chosun Biz
Johnson & Johnson, Kenvue slammed with state lawsuit over Tylenol autism claims - Insurance Business America
Texas sues Johnson & Johnson over Tylenol-autism link claims - KEYE
Texas Waves ‘MAHA’ Flag With Complaint Alleging Autism Link To Prenatal Acetaminophen Exposure - Citeline News & Insights
Texas Sues Tylenol Makers, Claiming They Hid Autism Risks - The New York Times
Texas sues Kenvue claiming it hid link between Tylenol and autism - drugdiscoverytrends.com
Texas sues Tylenol makers J&J and Kenvue, claiming they hid drug's autism risks - Reuters
Kenvue hiring Mondelēz exec as new chief marketing officer amid Tylenol woes - Seeking Alpha
Texas sues Tylenol makers over disproven claims about autism - MSNBC News
Texas sues Tylenol makers over alleged links to autism, ADHD - Jurist.org
Mixed options sentiment in Kenvue Inc with shares down 3.55% - TipRanks
Exclusive | Embattled Tylenol Maker Kenvue Hires New Marketing Chief - The Wall Street Journal
Hold Rating for Kenvue, Inc.: Legal Challenges and Sales Decline Amidst Growth Potential - TipRanks
Texas AG Paxton sues Tylenol makers over alleged link to autism - NewsNation
Texas Suit Accuses Tylenol Maker of Hiding a Link to Autism - The Wall Street Journal
More Than 15,000 Neutrogena Makeup Wipes Packages Recalled - BeautyMatter
Texas AG sues Tylenol makers over pregnancy claims - Virginia Business
Texas AG sues makers of Tylenol over hiding alleged links to autism - Rural Radio Network
Kenvue readies defenses as Texas AG sues over alleged Tylenol-autism link - Fierce Pharma
Texas lawsuit against companies behind Tylenol asserts unproven claims of autism risk - statnews.com
Ken Paxton Alleges Johnson & Johnson Misled Mothers On Tylenol Safety - Benzinga
Texas sues Tylenol maker in wake of Trump’s unfounded autism warnings - The Hill
Tylenol Is Tied to Autism, Texas Claims in Suit. Kenvue Stock Shudders. - Barron's
Who makes Tylenol? Who owns Kenvue? Texas sues Tylenol over alleged autism, Tylenol link - Bergen Record
Ken Paxton sues the maker of Tylenol over claims the painkiller causes autism - Houston Chronicle
Texas Attorney General Ken Paxton files Tylenol lawsuit over autism claims - CBS News
Texas Sues J&J, Kenvue for Alleged Deception in Acetaminophen Marketing - The American Journal of Managed Care® (AJMC®)
Texas AG Ken Paxton sues Tylenol makers, alleging risks of autism - KERA News
Is There an Opportunity in Kenvue After Its 29% Drop in 2025? - simplywall.st
10 Most Buzzing Stocks to Buy with Huge Upside Potential - Insider Monkey
Kenvue Inc Stock (KVUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):